Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

In this video, Erica L. Mayer, MD, MPH, discusses the SERENA-6 study, which assessed the efficacy of switching to camizestrant plus a CDK 4/6 inhibitor vs. continuing standard treatment among patients ...

Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antonio Carlos, 6627, CEP 31270-901, Belo Horizonte, Brazil, and College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii ...